-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $330 MILLION SERIES B FINANCING TO ADVANCE GLOBAL PHASE 3 DEVELOPMENT OF IBI324 (OLN324) IN DME AND WET AMD; STUDIES COMMENCING IN SECOND HALF OF 2026

Reuters·06/25/2026 00:00:01

Please log in to view news